AACR Offers 1998 Elion Award and Research Fellowships

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 11
Volume 6
Issue 11

PHILADELPHIA-The American Association for Cancer Research (AACR) is seeking applications for its sixth annual Gertrude B. Elion Cancer Research Award, as well as Research Fellowships for young scientists.

PHILADELPHIA—The American Association for Cancer Research (AACR) is seeking applications for its sixth annual Gertrude B. Elion Cancer Research Award, as well as Research Fellowships for young scientists.

The one-year, $30,000 Elion Award is provided through an educational grant from GlaxoWellcome Oncology. It is open to nontenured assistant professors doing clinical, basic, translational, or prevention research in the United States and Canada.

The 1998 Research Fellowships are being sponsored by the AACR, Amgen, Bristol-Myers Squibb Oncology, the Cancer Research Foundation of America, Hoechst-Marion Roussel, and the Kimmel Foundation for Cancer Research. The fellowships are open to scientists who have been postdoctoral or clinical fellows at an academic institution in the Americas for at least 2 but not more than 5 years.

The deadlines for applications are December 15, 1997, for the Elion Award and January 15, 1998, for the Research Fellowships. For more information, contact Jenny Ann Horst-Martz, AACR, Public Ledger Building, 150 South Independence Mall West, Suite 826, Philadelphia, PA 19106; phone: 215-440-9300; fax: 215-440-9372; email: horst@aacr.org.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
2 experts in this video
Related Content